A new drug is being studied on its effectiveness to the autoimmune disorder Multiple Sclerosis; Tyrosine Kinase Inhibitors. Its actual results still remain a promise to solving and finding a disease to Multiple Sclerosis however much research and studies are still needed. Tyrosine Kinases are intracellular enzymes that control cell differentiation, proliferation, and survival. They program and promote cell growth and death and have already been used to regulate metabolism. These inhibitors limit the activation of B cells that affect Multiple Sclerosis. Mastinib and Bruton’s tyrosine kinase inhibitors are primarily being studied to target mast cells and macrophages that are near and inside the human nervous system. Bruton tyrosine kinase inhibitors affect blood-based cells and are used throughout the blood system of a human body. Microglia are more effective for Progressive MS which are associated with B cells that these inhibitors can become useful towards.
TKIs have been sowing the potential these inhibitors have in the treatment of multiple sclerosis. Fingolimod, an inhibitor created as a sphingosine-1-phosphate receptor modulator, has shown effects on various tyrosine kinases and is reducing the frequency of MS relapses in clinical trials while testing tyrosine kinase inhibitors. After one trial of Masitinib it was shown to be affecting immune cell activation and neuroinflammation, the trials have shown reduction in relapse rates and disability progression observed compared to placebo. Not only that but Tyrosine Kinase Inhibitors also increase neuroprotection and remyelination reducing the effects of multiple sclerosis and help advance patients' lives.
However, using Tyrosine Kinase Inhibitors aren’t fully developed and aren’t certified as safe to use in actual patients and scenarios. Currently clinical investigations are being held to determine whether tyrosine kinase meets the long-term safety and target standards for addressing multiple sclerosis. Not only that but a recent phase 2 study has shown that Masitinib has caused small cases and signs of disability within multiple sclerosis patients. Overall tyrosine kinase inhibitors are becoming more promising in targeting the effectiveness and root cause of multiple sclerosis and addressing this disease once and for all.
References
Hot topics in MS: Tyrosine kinases inhibitors studied for treatment of MS. (2022, December 19). Rocky Mountain MS Center. https://mscenter.org/article/hot-topics-in-ms-tyrosine-kinases-inhibitors-studied-for-treatment-of-ms/
Multiple sclerosis - Diagnosis and treatment - Mayo Clinic. (2022, December 24). Top-ranked Hospital in the Nation – Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/diagnosis-treatment/drc-20350274
Tyrosine kinase inhibitors (TKIs). (n.d.). Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/24984-tyrosine-kinase-inhibitors
Comments